SSY Group (HKG:2005) has obtained drug production and registration approval for its phenylephrine hydrochloride injection from China's National Medical Products Administration, a Tuesday bourse filing said.
The approval came as the drug passed the regulator's consistency evaluation.
The drug is mainly used to maintain blood pressure during anesthesia and treatment of shock, as well as to control paroxysmal supraventricular tachycardia.
Shares of the pharmaceutical company were up nearly 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments